Quick navigation menu :

  1. Go to the content
  2. Go to the main sections menu
  3. Go to the search engine
  4. Go to the help menu
  5. Go to the modules
  6. Go to the shortcuts list

Help menu :

  1. Sanofi Worldwide |
     
  2. US Web Sites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Sitemap |
  6. Help
  1. Font size

    Reduce font size Increase font size  
 
 

Executive leadership

Content :

Executive Leadership

Sanofi North America Leadership

 

Bernard Amoury
Head of Global Supply Chain 
Based in Croix de Berny, France

Bernard Amoury is Vice President, Global Supply Chain. In this role, Bernard leads the Supply Chain team with a strong focus on customer service, economical performance, coordinated distribution strategy and sustainable development.

With previous experience in military research and energy-saving projects, Bernard joined Sanofi in 1989 and held several roles of increasing responsibility across functions, including serving as Financial Controller of Chemical Operations and Head of Industrial Affairs U.S. before being appointed to his current role in 2006.

He studied industrial and mechanical engineering at Arts et Métiers in France and earned his MBA in finance from the University of Paris.

 

Marc Bonnefoi, DVM, Ph.D. 
Head of the North America R&D Hub and Vice President of Disposition, Safety and Animal Research Scientific Core Platform, Sanofi
Based in Bridgewater, N.J.

Marc Bonnefoi is Head of the North America R&D Hub and Vice President, Disposition, Safety and Animal Research (DSAR) Scientific Core Platform. In this role, he oversees all R&D activities in North America, including the Sanofi Boston R&D Hub, Tucson Research Center, Sanofi Pasteur R&D, the Genzyme San Antonio R&D site, Canadian Clinical Study Unit, Merial R&D and the North America Development Center.

Prior to this role, he was the Global Head of Drug Safety Evaluation, responsible for the nonclinical safety evaluation of all drug candidates, the management of toxicology, pathology and safety pharmacology operations at all sites, and the sciences of safety assessment.

Marc earned a doctorate in veterinary medicine and a doctorate in pharmacology from the University of Toulouse in France.

 

Damian Braga
Senior Vice President, Commercial Operations, Sanofi Pasteur
Based in Swiftwater, Pa.

As Senior Vice President, Commercial Operations for the Vaccines business, Damian is responsible for protecting our vaccines leadership in developed markets and building our presence in emerging markets. 

Damian joined the company as a financial analyst in 1988 and moved through various roles of increasing responsibility, becoming President of Sanofi Pasteur US in 2002 and head of The Americas in 2007 before being named to his current Global role in 2011.

He earned a bachelor’s degree in economics from the University of Miami and an MBA from Seton Hall University.

 

Gregory Irace
Senior Vice President, Global Services, Sanofi

Gregory is Senior Vice President, Global Services for Sanofi, one of the world's largest healthcare solutions companies. Greg is the chairman of the U.S. Regional Strategic Management Committee. He is also responsible for operating support services for all of Sanofi's operations in North America, including Finance, Purchasing, Human Resources, Communications, Corporate Affairs, Legal, Supply Chain, Compliance, Site Services and Information Solutions, as well as contributing to the governance of support services globally. Finally, he is responsible for leading Global Information Solutions strategy and managing Global Information Solutions operations. He is a member of Sanofi's Global Leadership Team.

Prior to his current role, from February 2007 to August 2011, Gregory was President and CEO of Sanofi US/Canada Pharmaceutical Operations, with responsibility for the Pharmaceuticals business in the U.S., Canada and Puerto Rico, as well as leading coordination of Industrial Affairs and R&D activities in the U.S. Greg has served the company in various capacities of increasing responsibility with Sanofi and its legacy companies since 1991, including U.S. Chief Financial Officer from October 1994 to February 2007.

He began his career by working at Price Waterhouse for 11 years where, as a mergers and acquisitions consultant, Gregory worked on the formation of the Sanofi/Sterling alliance.

Gregory earned a bachelor's degree in accounting from the State University of New York at Albany and was a certified public accountant. He is a member of the Board of Directors of the U.S. Chamber of Commerce, Chairman of the Health Leadership Council and Chairman of the Corporate Council of the Children's Health Fund.

 

David Meeker, M.D.
Chief Executive Officer, Genzyme
Based in Cambridge, Mass.

David was appointed Chief Executive Officer of Genzyme in October 2011, with responsibility for leading the Personalized Genetic Health and Multiple Sclerosis businesses.

David joined Genzyme in 1994 as Medical Director and has held key positions of increasing responsibility as he led the development of treatments in the current rare disease portfolio. As President of the Global rare disease business, he oversaw the global launches of Aldurazyme, Fabrazyme and Myozyme. In 2009, he was promoted to Chief Operating Officer of Genzyme and has played an important role in the integration with Sanofi.

He earned his doctor of medicine degree from the University of Vermont Medical School and completed the Advanced Management Program at Harvard Business School in 2000.

 

Tal ZAKS, M.D., Ph.D.
VP, Interim Head
Global Oncology Division

Tal Zaks is the VP of Oncology Development at Sanofi in Cambridge, MA responsible for leading the clinical development of compounds through regulatory registration and the Interim Head of Sanofi Oncology.

Tal began his industry career at GlaxoSmithKline in the Genetics Research group, where he built an oncology translational medicine team and led genetics, translational, and clinical research on lapatinib as well as the in-licensing and clinical development of foretinib.

Tal received his MD/PhD degree from the Ben Gurion University in Israel and completed his clinical training in internal medicine at Temple University Hospital followed by a fellowship in medical oncology at the University of Pennsylvania. In addition to his work at Sanofi, Tal currently serves as an adjunct Associate Professor of Medicine at the University of Pennsylvania.

 

Anne Whitaker
President, North America Pharmaceuticals

Anne leads Sanofi’s pharmaceuticals business in North America. She oversees all operations within the region including the Diabetes, Oncology, Cardiovascular and other Patient Centered Units, U.S. Market Access, U.S. Medical Affairs, Business Strategy, Planning & Operations, Chattem (Consumer Healthcare), and Canada Pharmaceuticals. Anne serves as a member of the Global Management Committee, the Global Operations Committee and the U.S. Regional Strategic Management Committee.

A distinguished and dedicated professional with more than 20 years of experience, Anne began her career at Delta Communications and joined the Upjohn Company in 1991 as a metabolic disease specialist. She joined GlaxoSmithKline in 1992 as a sales representative and held various leadership positions in the Commercial organization. In 2001, she became Vice President of Critical and Supportive Care before being appointed Senior Vice President of Leadership and Organization Development from 2008 to 2009. In 2009, Anne became Senior Vice President and Business Unit Head, Cardiovascular, Metabolic and Urology (CVMU) at GlaxoSmithKline, where she had full commercial responsibility for leading, developing and managing strategic performance of the CVMU business. She was appointed to her present position at Sanofi in September 2011.

Anne holds a bachelor's degree in Chemistry and Business Administration from the University of North Alabama.

 

Thomas Zerzan
President, Merial North America
Based in Duluth, Ga.

Thomas Zerzan is a member of Merial’s Leadership Team and serves as President of the North American Animal Health business, which has grown to be one of the world’s leading providers of veterinary products through sales of Frontline, Heartgard, Ivomec, GastroGard and other industry-leading brands. 

He began his career at the Colgate-Palmolive Company, where he was promoted through a number of management positions both in North America and internationally. Prior to joining Merial 11 years ago, Thomas served as General Manager of one of Colgate-Palmolive’s operations.

 

Last update: December 03, 2013